MiRagen Therapeutics, a Boulder, CO-based biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics primarily for the treatment of patients who suffer from cardiovascular and muscle disease, completed a $20m Series B financing.
The round was led by Remeditex Ventures, with participation from existing investors Atlas Venture, Boulder Ventures, Amgen Ventures, and Broadview Ventures.
Led by William S. Marshall, Ph.D., President and CEO, miRagen Therapeutics intends to use the funding to develop innovative microRNA-based therapeutics for cardiovascular and muscle disease.
MicroRNAs have emerged as an important class of small RNAs encoded in the genome. They act to control the expression of sets of genes and entire pathways and are thus thought of as master regulators of gene expression representing potential drug targets for controlling many biologic and disease processes.